Cargando…

Current Main Topics in Multiple Myeloma

SIMPLE SUMMARY: In newly diagnosed multiple myeloma patients (NDMM) the introduction of three-drug, and recently, four-drug combinations allowed to reach response rates never seen before, leading to significantly improved PFS and OS. Long-term therapies play a key role in delaying or preventing rela...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morè, Sonia, Corvatta, Laura, Manieri, Valentina Maria, Olivieri, Attilio, Offidani, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136770/ https://www.ncbi.nlm.nih.gov/pubmed/37190132 http://dx.doi.org/10.3390/cancers15082203

Ejemplares similares

P973: ATTRITION PROBABILITY AND PREDICTORS AMONG MULTIPLE MYELOMA PATIENTS TREATED IN AN ITALIAN HAEMATOLOGICAL TERTIARY CARE CENTRE
por: More’, Sonia, et al.
Publicado: (2023)

Novel Experimental Drugs for Treatment of Multiple Myeloma
por: Offidani, Massimo, et al.
Publicado: (2021)

P912: ADDING REFRACTORINESS STATUS TO LINES OF THERAPY BETTER DEFINE PROGNOSIS OF A REAL LIFE ITALIAN MULTIPLE MYELOMA POPULATION
por: More’, Sonia, et al.
Publicado: (2023)

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
por: Offidani, Massimo, et al.
Publicado: (2021)

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
por: Morè, Sonia, et al.
Publicado: (2022)

Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2023)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2020)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

P47 REAL-WORLD DATA OF ATTRITION RATES BY SUBSEQUENT LINES OF THERAPY IN MULTIPLE MYELOMA PATIENTS TREATED IN A TERTIARY CARE ITALIAN CENTRE
por: Morè, S., et al.
Publicado: (2023)

P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
por: Morè, S, et al.
Publicado: (2022)

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
por: Offidani, Massimo, et al.
Publicado: (2014)

Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
por: Morè, Sonia, et al.
Publicado: (2023)

PB2024: PREVALENCE OF TYPE 1 GAUCHER DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: FIRST INTERIM ANALYSIS OF A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY
por: Offidani, M., et al.
Publicado: (2022)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration
por: Nabissi, Massimo, et al.
Publicado: (2016)

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
por: Offidani, M, et al.
Publicado: (2013)

Experts’ consensus on the definition and management of high risk multiple myeloma
por: Marcon, Chiara, et al.
Publicado: (2023)

Current and Novel Alkylators in Multiple Myeloma
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Current and Future PET Imaging for Multiple Myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2023)

Consolidation in multiple myeloma – current status and perspectives
por: Olszewska-Szopa, Magdalena, et al.
Publicado: (2014)

Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
por: Bobin, Arthur, et al.
Publicado: (2020)

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
por: Abramson, Hanley N.
Publicado: (2023)

Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
por: Swan, Dawn, et al.
Publicado: (2019)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Role of Galectins in Multiple Myeloma
por: Storti, Paola, et al.
Publicado: (2017)

Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives
por: Barreto, Igor Valentim, et al.
Publicado: (2022)

Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2023)

Physical Activity in Multiple Myeloma: A Review of the Current Literature
por: Hillengass, Michaela, et al.
Publicado: (2023)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
por: Mogollón, Pedro, et al.
Publicado: (2019)

Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma
por: Claveau, Jean-Sébastien, et al.
Publicado: (2022)

T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments
por: Simmons, Gary L., et al.
Publicado: (2022)

Oncolytic Virotherapy and Microenvironment in Multiple Myeloma
por: Marchica, Valentina, et al.
Publicado: (2021)

Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors
por: Valković, Toni, et al.
Publicado: (2015)

Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives
por: Kulig, Piotr, et al.
Publicado: (2023)

Smoldering multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2022)

MYC inhibitors in multiple myeloma
por: Martínez-Martín, Sandra, et al.
Publicado: (2021)

Multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2020)

Current and Emerging Treatments for Multiple Myeloma
por: Schwartz, Rowena N., et al.
Publicado: (2008)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5ah2aeei5v1r1drjjrgp62lqbi